65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update
Authors
Keywords
-
Journal
ENDOCRINE-RELATED CANCER
Volume 25, Issue 8, Pages T159-T169
Publisher
Bioscientifica
Online
2018-03-14
DOI
10.1530/erc-18-0015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
- (2017) Waseem Touma et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
- (2017) Martin J van den Bent et al. LANCET
- MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas
- (2017) Alexander S. G. Micko et al. Pituitary
- Is there a role for early chemotherapy in the management of pituitary adenomas?
- (2016) Andrew L. Lin et al. NEURO-ONCOLOGY
- The role of combination medical therapy in the treatment of acromegaly
- (2016) Dawn Shao Ting Lim et al. Pituitary
- How effective is temozolomide for treating pituitary tumours and when should it be used?
- (2016) Carmel Halevy et al. Pituitary
- MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
- (2016) Olivier J. Switzeny et al. Clinical Epigenetics
- Invasive, Atypical and Aggressive Pituitary Adenomas and Carcinomas
- (2015) Aydin Sav et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center
- (2015) Filippo Ceccato et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
- (2015) Marco Losa et al. JOURNAL OF NEURO-ONCOLOGY
- Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina
- (2015) Oscar D. Bruno et al. International Journal of Endocrinology
- Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications
- (2015) Christian P. Miermeister et al. Acta Neuropathologica Communications
- Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma
- (2014) Ayca Ersen et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Aggressive pituitary adenomas—diagnosis and emerging treatments
- (2014) Antonio Di Ieva et al. Nature Reviews Endocrinology
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- The Role of Temozolomide in the Treatment of a Patient with a Pure Silent Pituitary Somatotroph Carcinoma
- (2013) Leonardo Neto et al. Endocrine Practice
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-term treatment with temozolomide in malignant glioma
- (2013) Jonathan P. Mannas et al. JOURNAL OF CLINICAL NEUROSCIENCE
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- Temozolomide-Related Hematologic Toxicity
- (2013) Claudia Scaringi et al. ONKOLOGIE
- Temozolomide in the management of dopamine agonist-resistant prolactinomas
- (2012) B. C. Whitelaw et al. CLINICAL ENDOCRINOLOGY
- Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
- (2011) Shlomo Melmed et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pituitary Carcinoma: Difficult Diagnosis and Treatment
- (2011) Anthony P. Heaney JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas
- (2011) Fateme Salehi et al. JOURNAL OF NEURO-ONCOLOGY
- Pathogenesis of pituitary tumors
- (2011) Shlomo Melmed Nature Reviews Endocrinology
- New targeted therapies in pituitary carcinoma resistant to temozolomide
- (2011) Emmanuel Jouanneau et al. Pituitary
- Anti-VEGF therapy in pituitary carcinoma
- (2011) Leon D. Ortiz et al. Pituitary
- Treatment of pituitary neoplasms with temozolomide
- (2010) Luis V. Syro et al. CANCER
- Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome
- (2010) Fateme Salehi et al. ENDOCRINE PATHOLOGY
- SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases
- (2010) H. Bode et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT immunoexpression in aggressive pituitary adenoma and carcinoma
- (2010) Queenie Lau et al. Pituitary
- O6-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas
- (2009) Georg Widhalm et al. CANCER
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
- (2009) C Hagen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Management of aggressive pituitary adenomas: current treatment strategies
- (2008) Michael Buchfelder Pituitary
- Mechanisms of Disease: temozolomide and glioblastoma—look to the future
- (2008) Maciej M Mrugala et al. Nature clinical practice. Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started